Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLYSYN
- Development stage
- Phase 2
- Lead developer
- VERAXA Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FLYSYN is a chimeric, Fc-optimized monospecific IgG1 monoclonal antibody that specifically targets the extracellular domain of the Fms-like tyrosine kinase 3 (FLT3, also known as CD135), which is abundantly expressed on acute myeloid leukemia (AML) cells. Its mechanism of action includes antibody-dependent cell cytotoxicity and stimulation of T lymphocytes. The drug is being developed primarily for the eradication of measurable residual disease (MRD) in AML patients who are in complete remission but remain MRD positive. Early clinical studies have shown that FLYSYN monotherapy is safe and well-tolerated, with promising preliminary efficacy data in reducing or eliminating MRD in AML patients[2][5][6].
- Brand names
- FLYSYN
- Other names
- 4G8-SDIEMVX-A901VX-A-901VX-A 901
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on FLYSYN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLYSYN.